Merus Gestione

Criteri Gestione verificati 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Jan van de Winkel

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	3.2yrs
Durata media del Consiglio di amministrazione	Nessun dato

Aggiornamenti recenti sulla gestione

Recent updates

Genmab Buys Merus For $8bn: A Good Deal If Potential Is Converted Into Revenue

Sep 29

Need To Know: The Consensus Just Cut Its Merus N.V. (NASDAQ:MRUS) Estimates For 2025

Mar 05

Earnings Update: Merus N.V. (NASDAQ:MRUS) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts

Mar 02

Merus N.V.'s Innovative Cancer Therapies: Balancing Its IP Potential With Financial Risks

Aug 14

Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)

May 24

Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement

Mar 01

Merus Stock: Rally Seems Overdone

Jan 23

Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M

Aug 08

Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies

Aug 02

Merus: Precision Oncology Pioneer Continues To Execute In The Clinic

Jun 30

AMMINISTRATORE DELEGATO

Jan van de Winkel

no data

Mandato

Dr. Jan G.J. van de Winkel, Ph D., is CEO & Executive Director of Merus N.V. from December 11, 2025. Dr. van de Winkel is a co-founder of Genmab and served as President, Research & Development and Chief Sc...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Gregory Perry	Chief Financial Officer	2.5yrs	US$3.26m	0% $ 0
Peter Silverman	EVP, Company Secretary	7.8yrs	US$3.40m	0% $ 0
Fabian Zohren	Chief Medical Officer	1.4yrs	US$7.20m	0% $ 0
Jan van de Winkel	CEO & Executive Director	no data	Nessun dato	Nessun dato
Hennie Hoogenboom	Co-Founder and Scientific Advisor	no data	Nessun dato	Nessun dato
Harry Shuman	Chief Accounting Officer	no data	Nessun dato	0% $ 0
Cornelis de Kruif	CTO & Executive VP	12.9yrs	US$609.22k	Nessun dato
Cecilia Anna Geuijen	Chief Scientific Officer & Senior VP	4.6yrs	Nessun dato	Nessun dato
Sherri Spear	Senior Vice President of Investor Relations & Strategic Communications	no data	Nessun dato	Nessun dato
Kathleen Farren	Director of IR & Corporate Communications Officer	no data	Nessun dato	Nessun dato
Audrey Bergan	Chief People Officer	1.1yrs	Nessun dato	Nessun dato
Shannon Campbell	Executive VP & Chief Commercial Officer	3.8yrs	Nessun dato	Nessun dato

3.2yrs

Durata media

59yo

Età media

Gestione esperta: Il team dirigenziale di MRUS è considerato esperto (durata media dell'incarico 3.2 anni).

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2025/12/31 12:47
Prezzo dell'azione a fine giornata	2025/12/29 00:00
Utili	2025/09/30
Utili annuali	2024/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Merus N.V. è coperta da 29 analisti. 15 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Matthew Venezia	Alliance Global Partners
Etzer Darout	Barclays
Evan Seigerman	BMO Capital Markets Equity Research

Merus Gestione

Criteri Gestione verificati 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Merus N.V., Annual General Meeting, May 21, 2025

Merus N.V. Announces Chief Medical Officer Changes

Merus N.V. Appoints Jason Haddock as Non-Executive Director

Merus N.V., Annual General Meeting, May 07, 2024

EVP, Company Secretary notifies of intention to sell stock

Merus Appoints Greg Perry as Chief Financial Officer

Recent updates

Merus N.V.(NasdaqGM:MRUS) dropped from NASDAQ Composite Index

Merus to Delist All Common Shares from Nasdaq

Merus N.V.(NasdaqGM:MRUS) dropped from NASDAQ Biotechnology Index

Genmab A/S (CPSE:GMAB) completed the acquisition of Merus N.V. (NasdaqGM:MRUS) in a tender offer transaction.

Genmab Buys Merus For $8bn: A Good Deal If Potential Is Converted Into Revenue

Genmab Reportedly in Advanced Talks to Buy Merus

Merus N.V. has completed a Follow-on Equity Offering in the amount of $300.000006 million.

Merus, N.V. Provides Updates on Clinical Development

Merus N.V. Announces Interim Data Demonstrates Robust Efficacy and Durability in 1L Pembrolizumab

Merus N.V., Annual General Meeting, May 21, 2025

Need To Know: The Consensus Just Cut Its Merus N.V. (NASDAQ:MRUS) Estimates For 2025

Earnings Update: Merus N.V. (NASDAQ:MRUS) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts

Here's Why We're Not Too Worried About Merus' (NASDAQ:MRUS) Cash Burn Situation

Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff

Merus N.V. Announces That the United States Food and Drug Administration Approves Bizengri (Zizengri) for Treatment Indicated for Adults with Pancreatic Adenocarcinoma or Non Small Cell Lung Cancer

Merus: Petosemtamab Set Up For December 2024 Data Presentation

Merus N.V. Announces First Patient Dosed in Liger-Hn1, A Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L R/M HNSCC

Merus N.V.'s Innovative Cancer Therapies: Balancing Its IP Potential With Financial Risks

Merus N.V. Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC

Merus N.V. Announces Chief Medical Officer Changes

Merus N.V. Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab At the 2024 ASCO® Annual Meeting

Merus N.V. has completed a Follow-on Equity Offering in the amount of $400.15 million.

Merus N.V. has filed a Follow-on Equity Offering in the amount of $300 million.

Price target increased by 21% to US$73.36

Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)

Consensus revenue estimates increase by 26%

Merus N.V. Announces Petosemtamab Grants Breakthrough Therapy Designation by the U.S. FDA

First quarter 2024 earnings released: US$0.59 loss per share (vs US$0.86 loss in 1Q 2023)

Merus N.V. Appoints Jason Haddock as Non-Executive Director

Merus N.V., Annual General Meeting, May 07, 2024

Price target increased by 7.6% to US$59.18

Merus N.V. announced that it has received $25.000035 million in funding from Gilead Sciences, Inc.

Full year 2023 earnings: EPS and revenues miss analyst expectations

Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement

Price target increased by 16% to US$51.60

Merus N.V. has filed a Follow-on Equity Offering in the amount of $300 million.

Merus Stock: Rally Seems Overdone

EVP, Company Secretary notifies of intention to sell stock

Consensus EPS estimates upgraded to US$2.60 loss

Consensus estimates of losses per share improve by 12%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Merus N.V. Announces Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

U.S. Food and Drug Administration Grants Second Breakthrough Therapy Designation for zenocutuzumab (Zeno) of Merus N.V

Merus Appoints Greg Perry as Chief Financial Officer

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates upgraded to US$3.63 loss

Independent Non Executive Director exercised options to buy US$1.5m worth of stock.

Price target increased by 8.6% to US$40.67

Price target increased by 8.5% to US$39.67

Chief Business Officer exercised options to buy US$1.9m worth of stock.

Full year 2022 earnings released: US$2.92 loss per share (vs US$1.73 loss in FY 2021)

Now 21% undervalued

Merus N.V. Announces Executive Changes

Price target decreased to US$37.11

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$38.44

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M

Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies

Merus: Precision Oncology Pioneer Continues To Execute In The Clinic

Consensus revenue estimates increase by 15%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Executive VP exercised options and sold US$947k worth of stock

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 17%